Upregulating substance P levels to treat obstructive sleep apnea

Bibliography

• Severini C, Improta G, Falconieri-Erspamer G, et al. The tachykinin peptide family. Pharmacol Rev 2002;54:285-322
   PubMed Web of Science ®Google Scholar
• Krase W, Koch M, Schnitzler HU. Substance P is involved in the sensitization of the acoustic startle response by footshocks in rats. Behav Brain Res 1994;63:81-8
   PubMedGoogle Scholar
• Kotani H, Hoshimaru M, Nawa H, Nakanishi S. Structure and gene organization of bovine neuromedin K precursor. Proc Natl Acad Sci USA 1986;83:7074-8
   PubMedGoogle Scholar
• Zhang Y, LU L, Furlonger C, et al. Hemokinin is a hematopoietic-specific tachykinin that regulates B lymphopoiesis. Nat Immunol 2000;1:392-7
   PubMed Web of Science ®Google Scholar
• Maggi CA. The mammalian tachykinin receptors. Gen pharmacol 1995;26:911-44
   PubMedGoogle Scholar
• Maggi CA, Schwartz TW. The dual nature of the tachykinin NK1 receptor. Trends Pharmacol 1997;18:351-5
   PubMed Web of Science ®Google Scholar
• Almeida TA, Rojo J, Nieto PM, et al. Tachykinins and tachykinin receptors: structure and activity relationships. Curr Med Chem 2004;11:2045-81
   PubMed Web of Science ®Google Scholar
• Patacchini R, Lecci A, Holzer P, et al. Newly discovered tachykinins raise new questions about their peripheral roles and the tachykinin nomenclature. Trends Pharmacol Sci 2004;25:1-3
   PubMed Web of Science ®Google Scholar
• Rigby M, O'Donnell R, Rupniak NM. Species differences in tachykinin receptor distribution: further evidence that the substance P (NK1) receptor predominates in human brain. J Comp Neurol 2005;490:335-53
   PubMed Web of Science ®Google Scholar
• Pennefather JN, Lecci A, Candenas ML, et al. Tachykinins and tachykinin receptors: a growing family. Life Sci 2004;74:1445-63
   PubMed Web of Science ®Google Scholar
• Schwarz MJ, Spath M, Muller-Bardorff H, et al. Relationship of substance P, 5-hydroxidole acetic acid and tryptophan in serum fibromyalgia patients. Neurosci Lett 1999;259:196-8
   PubMed Web of Science ®Google Scholar
• Vaeroy H, Helle R, Terenis L. Elevated CSF levels of substance P and high incidence of Raynaud's phenomenon in patients in fibromyalgia: new features for diagnosis. Pain 1988;32:21-6
   PubMed Web of Science ®Google Scholar
• Quartara L, Maggi CA. The tachykinin NK1 receptor. Part II. Distribution and pathophysiological roles. Neuropeptides 1998;32:1-49
   PubMed Web of Science ®Google Scholar
• Rupniak NMJ, Carlson EC, Harrison T, et al. Pharmacological blockade or genetic deletion of substance P (NK1) receptors attenuates neonatal vocalization in guinea pigs an mice. Neuropharmacology 2000;39:1413-21
   PubMed Web of Science ®Google Scholar
• Santarelli L, Gobbi G, Debs PC, et al. Genetic and pharmacological disruption of neurokinin 1 receptor function decreases anxiety-related behaviors and increases serotonergic function. Proc Natl Acad Sci USA 2001;98:1912-7
   PubMed Web of Science ®Google Scholar
• Lacoste B, Riad M, Descarries L. Immunocytochemical evidence for the existence of substance P receptor (NK1) in serotonin neurons of rat and mouse dorsal raphe nucleus. Eur J Neurosci 2006;23:2947-58
   PubMedGoogle Scholar
• Nattie EE, LI A. Substance P-saporin lesion of neurons with NK1 receptors in one chemoreceptor site in rats decreases ventilation and chemosensitivity. J Physiol 2002;544:603-16
   PubMedGoogle Scholar
• Kohlmeier KA, Burns J, Reiner PB, Semba K. Substance P in the descending cholinergic projection to REM sleep-induction regions of the rat pontine reticular formation: anatomical and electrophysiological analyses. Eur J Neurosci 2002;15:176-96
   PubMedGoogle Scholar
• Zhang G, Wang L, Liu H, Zhang J. Substance P promotes sleep in the ventrolateral preoptic area of rats. Brain Res 2004;1028:225-32
   PubMed Web of Science ®Google Scholar
• Andersen ML, Nascimento DC, Machado RB, et al. Sleep disturbance induced by substance P in mice. Behav Brain Res 2006;167:212-8
   PubMed Web of Science ®Google Scholar
• Lieb K, Ahlvers K, Dancker K, et al. Effects of the neuropeptide substance P on sleep, mood, and neuroendocrine measures in healthy young men. Neuropsychopharmacology 2002;27:1041-9
   PubMed Web of Science ®Google Scholar
• Carpenter LL, Bayat L, Moreno F, et al. Decreased cerebrospinal fluid concentrations of substance P in treatment-resistant depression and lack of alteration after acute adjunct vagus nerve stimulation therapy. Psychiatry Res 2008;157:123-9
   PubMed Web of Science ®Google Scholar
• ASDA-Diagnostic Classification Steering Committee. The International Classification of Sleep Disorders. In: Lawrance KS, Diagnostic and coding manual. 2nd edition. Allen Press, Inc.; 1997
   Google Scholar
• Hedner J, Grote L. Cardiovascular concequences of obstructive sleep apnea. Eur Respir Mon 1998;10:227-65
   Google Scholar
• Bixler EO, Vgontzas AN, Lin H-M, et al. Prevalence of sleep-disordered breathing in women; effects of gender. Am J Respir Crit Care Med 2001;163:608-13
   PubMed Web of Science ®Google Scholar
• Engleman HM, Kingshott RN, Wraith PK, et al. Randomized placebo-controlled crossover trial of continuous positive airway pressure for mild sleep apnea/hypopnea syndrome. Am J Respir Crit Care Med 1999;159:461-7
   PubMed Web of Science ®Google Scholar
• Kapur VK, Baldwin CM, Resnick HE, et al. Sleepiness in patients with moderate to severe sleep-disordered breathing. Sleep 2005;28:472-7
   PubMed Web of Science ®Google Scholar
• Guilleminault C, Partinen M, Quera-Salva MA, et al. Determinants of daytime sleepiness in obstructive sleep apnea. Chest 1988;94:32-7
   PubMedGoogle Scholar
• Kramer MS, Winokur A, Kelsey J, et al. Demonstration of the efficacy and safety of a novel substance P (NK1) receptor antagonist in major depression. Neuropsychopharmacology 2004;29:385-92
   PubMed Web of Science ®Google Scholar
• Otsuka M, Yoshioka K. Neurotransmitter functions of mammalian tachykinins. Physiol Rev 1993;73:229-308
   PubMed Web of Science ®Google Scholar
• Kramer MS, Cutler N, Feighner J, et al. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science 1998;281:1640-5
   PubMed Web of Science ®Google Scholar
• Strittmatter M, Isenberg E, Grauer MT, et al. CSF substance P somatostatin and monoaminergic transmitter metabolites in patients with narcolepsy. Neurosci Lett 1996;218:99-102
   PubMedGoogle Scholar
• Ursavas A, Karadag M, Ilcol YO, et al. Relationship between serum substance P levels and daytime sleepiness in obstructive sleep apnea syndrome. Chest 2007;131:1400-5
   PubMedGoogle Scholar
• Silverberg DS, Oksenberg A. Are sleep-related breathing disorders important contributing factors to the production of essential hypertension? Curr Hypertens Rep 2001;3:209-15
   PubMedGoogle Scholar
• Worsnop CJ, Naughton MT, Barter CE, et al. The prevalence of obstructive sleep apnea in hypertensives. Am J Respir Crit Care Med 1998;157:111-5
   PubMed Web of Science ®Google Scholar
• Narkiewicz K, van de Borne PJ, cooley RL, et al. Sympathetic activity in obese subjects with and without obstructive sleep apnea. Circulation 1998;98:772-6
   PubMed Web of Science ®Google Scholar
• Calhoun DA, Nishizaka MK, Zaman MA, Harding SM. Aldosterone excretion among subjects with resistant hypertension and symptoms of sleep apnea. Chest 2004;125:112-7
   PubMed Web of Science ®Google Scholar
• Brooks D, Horner RL, Kozar LF, et al. Obstructive sleep apnea as a cause of systemic hypertension. Evidence from a canine model. J Clin Invest 1997;99:106-9
   PubMed Web of Science ®Google Scholar
• Pepperell JC, Ramdassingh-DOW S, Crosthwaite N, et al. Ambulatory blood pressure after therapeutic and subtherapeutic nasal continuous positive airway pressure for obstructive sleep apnoea: a randomised parallel trial. Lancet 2002;359:204-10
   PubMed Web of Science ®Google Scholar
• Becker HF, Jerrentrup A, Ploch T, et al. Effect of nasal continuous positive airway pressure treatment on blood pressure in patients with obstructive sleep apnea. Circulation 2003;107:68-73
   PubMed Web of Science ®Google Scholar
• Fiscus RR, Gross DR, Hao H, et al. N omega-nitro-L-arginine blocks the second phase but not the first phase of the endothelium-dependent relaxations induced by substance P in isolated rings of pig carotid artery. J Cardiovasc Pharmacol 1992;20(Suppl 12):S105-8
   Google Scholar
• Emonds-Alt X, Doutremepuich JD, Heaulme M, et al. In vitro and in vivo biological activities of SR140333, a novel potent non-peptide tachykinin NK1 receptor antagonist. Eur J Pharmacol 1993;250:403-13
   PubMed Web of Science ®Google Scholar
• Fu CY, Kong ZQ, Long Y, et al. Cardiovascular responses to rat/mouse hemokinin-1, a mammalian tachykinin peptide: Systemic study in anesthetized rats. Eur J Pharmacol 2007;572:175-81
   PubMedGoogle Scholar
• Robinson GV, Smith DM, Langford BA, et al. Continuous positive airway pressure does not reduce blood pressure in nonsleepy hypertensive OSA patients. Eur Respir J 2006;27:1229-35
   PubMed Web of Science ®Google Scholar
• Elliot R. Executive fuctions and their disorders. Br Med Bull 2003;65:49-59
   PubMed Web of Science ®Google Scholar
• Bartlett DJ, Rae C, Thompson CH, et al. Hippocampal area metabolites relate to severity and cognitive function in obstructive sleep apnea. Sleep Med 2004;5:593-6
   PubMed Web of Science ®Google Scholar
• van Dongen HP, Maislin G, Mullington JM, Dinges DF. The cumulative cost of additional wakefulness: dose-response effects on neurobehavioral functions and sleep physiology from chronic sleep restriction and total sleep deprivation. Sleep 2003;26:117-26
   PubMed Web of Science ®Google Scholar
• Thomas RJ, Rosen BR, Stern CE, et al. Functional imaging of working memory in obstructive sleep-disordered breathing. J Appl Physiol 2005;98:2226-34
   PubMed Web of Science ®Google Scholar
• Hasenöhrl RU, Souza-Silva MA, Nikolaus S, et al. Substance P and its role in neural mechanisms governing learning, anxiety and functional recovery. Neuropeptides 2000;34:272-80
   PubMedGoogle Scholar
• Ukai M, Shinkai N, Ohashi K, Kameyama T. Substance P markedly ameliorates scopolamine-induced impairment of spontaneous alternation performance in the mouse. Brain Res 1995;673:335-8
   PubMedGoogle Scholar
• Hasenöhrl RU, Frisch C, Nikolaus S, Huston JP. Chronic administration of neurokinin SP improves maze performance in aged Rattus norvegicus. Behav Neural Biol 1994;62:110-20
   PubMedGoogle Scholar
• Siuciak JA, Mccarthy SA, Martin AN, et al. Disruption of the neurokinin-3 receptor (NK3) in mice leads to cognitive deficits. Psychopharmacology (Berl) 2007;194:185-95
   PubMed Web of Science ®Google Scholar
• Grunstein RR, Handelsman DJ, Lawrence SJ, et al. Neuroendocrine dysfunction in sleep apnea: reversal by continuous positive airways pressure therapy. J Clin Endocrinol Metab 1989;68:352-8
   PubMed Web of Science ®Google Scholar
• Gambineri A, Pelusi C, Pasquali R. Testosterone levels in obese male patients with obstructive sleep apnea syndrome: relation to oxygen desaturation, body weight, fat distribution and the metabolic parameters. J Endocrinol Invest 2003;26:493-8
   PubMed Web of Science ®Google Scholar
• Meston N, Davies RJ, Mullins R, et al. Endocrine effects of nasal continuous positive airway pressure in male patients with obstructive sleep apnoea. J Intern Med 2003;254:447-54
   PubMed Web of Science ®Google Scholar
• Pennefather JN, Lecci A, Candenas ML, et al. Tachykinins and tachykinin receptors: a growing family. Life Sci 2004;74:1445-63
   PubMed Web of Science ®Google Scholar
• Pinto FM, Almeida TA, Hernandez M, et al. mRNA expression of tachykinins and tachykinin receptors in different human tissues. Eur J Pharmacol 2004;494:233-9
   PubMed Web of Science ®Google Scholar
• Sastry BV, Janson VE, Owens LK. Significance of substance P- and enkephalin-peptide systems in the male genital tract. Ann NY Acad Sci 1991;632:339-53
   PubMedGoogle Scholar
• Ravina CG, Seda M, Pinto FM, et al. A role for tachykinins in the regulation of human sperm motility. Hum Reprod 2007;22:1617-25
   PubMedGoogle Scholar